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1 • Specific Aims 
THROUGH 
06/30/94 
1. Design and synthesize specific peptide-related reversible transition-state inhibitors for human 
thrombin. 
2. Design and synthesize heterocyclic irreversible mechanism-based thrombin inhibitors. 
3. Utilize molecular modeling and the x-ray structure of human thrombin to improve the potency and 
specificity of both peptide and heterocyclic inhibitors. 
4. Evaluate the inhibitory potency and specificity of all new drugs in vitro. 
5. Evaluate the in vivo efficacy of the anti thrombotic agents in a rabbit thrombosis model. 
2 . Studies and Results 
Thrombin is a key enzyme in the coagulation pathway and synthetic inhibitors for thrombin are 
widely considered to have significant potential for treatment of various coagulation disorders. The goal of 
this research is the development of effective, specific and stable low-molecular weight synthetic inhibitors 
for thrombin and other enzymes in the coagulation pathway that participate in the formation of thrombin. 
During the past year we have focused our efforts on the synthesis of irreversible transition-state 
inhibitors and heterocyclic irreversible mechanism-based inhibitors for thrombin (specific aims 1 and 2). 
Dr. Richard Plaskon has been involved in molecular modeling studies with human thrombin (specific aim 
3). The inhibitory potency of the new compounds have been evaluated in vitro with both synthetic 
substrates and in coagulation tests (specific aim 4). Since we didn't obtain potent compounds until quite 
recently, no animal studies were performed in the last year (specific aim 5). 
Phosphonates as Inhibitors of Thrombin. We have focused most of our synthetic effort 
during the last year on peptidyl derivatives of diphenyl a-aminoalkylphosphonates. These compounds have 
been reported previously as specific and potent irreversible inhibitors of elastases, and various 
chymotrypsin-like enzymes. The inhibition mechanism involves the nucleophilic substitution on 
phosphorus atom by the active site serine to form a tetrahedral intermediate shown below (right). This 
phosphonate resembles the tetrahedral intermediate formed in substrate hydrolysis. Thus, we term these 
phosphonates as transition-state irreversible inhibitors. The leaving group in the phosphonylation is the 
electronegative phenoxy group. Good interactions of the amino acid side chain of the inhibitor with the S 1 
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We have synthesized phosphonate inhibitors containing the arginine analogs p-
amidinopheny lglycine and p-amidinophenylalanine, the structures are shown in the following figure. We 
also worked on a phosphonate arginine analog, but have not yet accomplished its synthesis. Various peptide 
'derivatives were synthesized including analogs with the D-Phe-Pro-Arg sequence which is a potent 
thrombin inhibitory sequence in derivatives such as peptide chloromethyl ketones. 
,OPh 




r. .... oPh 
0 
2, RCO-(p-AmPhe)P(OPh)2 
Several of the inhibitors are potent irreversible inhibitors of thrombin as measure by their second 
order inhibition rates kobsi[I]. The data are shown in the following table. One of the most effective 
derivatives is the Boc-D-Phe-Pro amidinophenylglycine derivative 5. We have also performed coagulation 
tests with these derivatives and fmd that several are effective anticoagulants (data not shown). 
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Table. Rates of Inhibition of Trypsin-like Serine Proteases by Peptidyl Derivatives of Diphenyl ( 4-






















































Thrombin has a central regulatory role in hemostasis and is formed by both the intrinsic and extrinsic 
pathways of blood coagulation. The major function of this serine protease is the cleavage of fibrinogen to. , . 
form fibrin clots, but thrombin also activates factor V, VITI, XIII and protein C which are important in the 
control of hemostasis and thrombosis. In addition, thrombin can stimulate platelet secretion and aggregation 
in blood, and mediate other nonhemostatic cellular events. 
Thrombin is a well recognized target for the design of new anti thrombotic agents since this serine 
protease is such a powerful trigger in thrombus formation in the blood. Considerable effort is being 
devoted to the development of new anti thrombotic agents since the cUITently available drugs such as heparin . 
often cause bleeding when used therapeutically and are unable to prevent the occlusive complications in 
atherosclerotic vascular disease or reocclusion following successful thrombolysis. Although much of this 
activity has been focused on high molecular weight thrombin inhibitors such as hirudin or low molecular 
weight platelet aggregation inhibitors, increasing research is being devoted to the development of suitable 
small synthetic thrombin inhibitors. In the future, it is likely that synthetic thrombin inhibitors will 
supplement or even replace currently used antithrombotic agents in a variety of therapeutic situations. 
The phosphonate inhibitors which we have developed in this research have the advantage to being 
stable in plasma, highly specific for their target protease and fairly potent. We believe they have 
considerable potential for development as antithrombotic agents. 
4. Plans 
Design and Synthesis. We plan to continue to improve the amidinophenylglycine and 
amidinophenylalanine derivatives as thrombin inhibitors and to extend this class of inhibitors to other 
enzymes particularly factor VTia and factor Xa. Dr. Plaskon has begun modeling studies with the 
phosphonates and we expect to be able to use his results to direct our design and synthesis work. Thus far 
it appears that the phosphonate are binding in an expect and unique manner to thrombin which should allow 
substantial improvement in their inhibition rates through struc~ modifications. 
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Vertebrate Animal Studies. Since no potent inhibitors were synthesized until recently, no 
animal work was carried out during the second year of this research. We plan to cany out preliminary 
animal studies shortly (May 1993) with three of the inhibitor molecules shown in Table I. 
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PROGRESS REPORT-DR. RICHARD R. PLASKON 
RESEARCH SUPPLEMENT TO PROMOTE THE RECRUITMENT OF INDIVIDUALS 
WITH DISABILITIES INTO BIOMEDICAL RESEARCH CAREERS 
A major portion of the research conducted by Dr. Plaskon during the fli'St year of this supplement 
involved the modeling of isocoumarin mechanism-based thrombin inhibitors into the active site of human a-
thrombin. The compounds modeled include the most potent derivatives of 4-chloro-3-
isothiureidoalkoxyisocoumarin inhibitors of human a-thrombin with various 7-amino substituents. A 
related isocoumarin thrombin inhibitor has previously been shown to be an anticoagulant in a rabbit model 
of coagulation. Dr. Plaskon's results are included in a manuscript which will shortly be submitted to the J. 
Medicinal Chemistry. 
To accomplish the energy minimizations required for the molecular modeling, semiempirical 
quantum mechanical calculations were successfully performed on portions of the human a-thrombin active 
site to obtain the partial atomic charges. Results of the modeling revealed that H-bonding between the Lys-
60F NH3 + of thrombin and the polar portion of the isocoumarin's 7-substituent was related to the 
inhibitor's potency. The potency of one inhibitor was correctly predicted from the calculation, but its 
potency was no greater than that of the other isocoumarin inhibitors modeled. From the modeling, Dr. 
Plaskon predict that an isocoumarin with a particular substituent would be expect to have greater potency. 
But thus far, we have been unable to isolate this isocoumarin for testing. 
A "leucine pocket" in the human a-thrombin active site was discovered while viewing the modeled 
structures. Based on the location of the pocket relative to that of the irreversible inhibitor D-Phe-Pro-Arg-
chloromethylketone (FPRCK) in the FPRCK-human a-thrombin complex crystal structure, it is thought 
that it might correspond to a S' site (i.e., a site where a side chain of an amino acid on the carbonyl side of 
the scissile bond interacts). In the second year of the supplement, Dr. Plaskon will determine what groups 
can interact with this pocket It is expected that long unbranched hydrocarbon chains would insert into the 
pocket. An isoleucine side chain might insert as well. 
To model inhibitors into the active site of thrombin, initial in vacuo inhibitor structures were 
obtained from semiempirical quantum mechanical calculations. These structures revealed that the orientation 
of the phenyl group of isocoumarin inhibitors which contain phenyl groups in their 7-substituent can be 
correlated with inhibitor potency. This result, combined with their modeling into the human a-thrombin 
active site, suggests that the phenyl group alters the relative orientation between the 7-substituent's polar 
region and the Lys-60F NH3 + of thrombin. Thus Dr. Plaskon is able to predict the inhibitory potency of 
new synthetic isocoumarin inhibitors before the compounds are synthesized. This results in a considerable 
savings in time and expense since only structures which have the greatest probability of being potent 
inhibitors will be synthesized. 
Dr. Plaskon has begun to model the binding of phosphonate inhibitors, in particular peptidyl 
derivatives of diphenyl (4-amidinophenylGly)- and (4-amidinoPhe)phosphonates, to the human a-thrombin 
active site. Semiempirical quantum mechanical calculations have been used to generate in vacuo structures 
of benzyloxycarbonyl derivatives of diphenyl (4-amidinophenylGly)- and (4-amidinoPhe)phosphonates. At 
present, only the benzyloxycarbonyl derivative of the diphenyl (4-amidinoPhe)phosphonate has been 
docked in thrombin's active site. A comparison of this docked structure with the X-ray crystal structure of 
D-Phe-Pro-Arg-chloromethylketone complexed with human a-thrombin was made. The D-Phe-Pro-
derivative of diphenyl (4-amidinoPhe)phosphonate can't bind to thrombin in an orientation similar to that of 
the chloromethyl ketone without altering the orientation of the phosphonate so that it will not easily react 
with the active site serine. This would explain the phosphonate's low inhibitory potency. Additional 
modeling studies will be conducted in the second year of the supplement to help determine if this 
explanation is correct Such studies should also reveal changes that could be made in the peptidyl groups 
which would result in phosphonate inhibitors of greater potency. 
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